Danish National Genome Center–Qiagen: genomic software tools, 202306– supply QCI Interpret software for oncology genome sequencing by Qiagen |
2023-06-13 |
Dynamic42–OTHER: investment, 202306 financing round Series A totalling mid-7-figure € incl a family office from the health sector |
2023-06-13 |
Dynamic42–SEVERAL: investment, 202306 financing round Series A mid-7-figure € incl investors bm-t + a familly office |
2023-06-13 |
Dynamic42–Thuringia (govt): investment, 202306 financing round Series A totalling mid-7-figure € incl existing investor bm-t |
2023-06-13 |
Chinook Therapeutics–Novartis: investment, 202306– acquisition $3.2b cash upfront + $300m cash milestones of Chinook by Novartis ANNOUNCED |
2023-06-12 |
Upstream Bio–SEVERAL: investment, 202306 financing round Series B $200m co-led by Enavate Sciences + Venrock Healthcare Capital Partners |
2023-06-08 |
OntoChem–Holtzbrinck: investment, 202306 acquisition 100% of OntoChem by Digital Science |
2023-06-07 |
Bayer–Acuitas Therapeutics: LNP technology, 202306– collab €na using LNP technology to deliver RNA payloads to liver |
2023-06-05 |
ITM–SEVERAL: investment, 202306 financing round €255m led by Temasek |
2023-06-05 |
Sartorius–Waters: biopharma production technology, 202306– collab expansion integration of PATROL UPLC PAS with Resolute BioSMB platform |
2023-06-05 |
4Pharma–BC Platforms: investment, 202306 acquisition €na of 4Pharma by BC Platforms |
2023-06-01 |
Bico–Swiss Life: real estate, 202306– leaseback 15y of property in Berlin by Scienion from BEOS Light Industrial Germany I fund |
2023-06-01 |
Swiss Life–Bico: real estate, 202306 acquisition €21m of new Scienion property in Berlin by BEOS Light Industrial Germany I fund |
2023-06-01 |
Synaffix–Lonza: investment, 202306 acquisition €100m upfront cash + €60m milestones of Synaffix by Lonza |
2023-06-01 |
Theragnostics–Ariceum Therapeutics: investment, 202306 acquisition 100% of Theragnostics Ltd for $2.5m cash upfront plus $41.5m milestones |
2023-06-01 |
Hookipa–SEVERAL: investment, 202305 public offering $50m with 22.9m common stock at $1.31/share plus 15,268 Series A-2 preferred stock at $1.310/each |
2023-05-31 |
Mithra Pharmaceuticals–BioConfidant: public relations, 202305 service existent by Cohesion Bureau |
2023-05-29 |
CARTemis Therapeutics–Germany (govt): grant, 202305– BMBF grant €4.6m to develop CAR T-cell therapy targeting CXCR5 (to MDC+Charité) |
2023-05-26 |
Michor Consulting–QbD Group: investment, 202305 acquisition of Michor Consulting by QbD Group |
2023-05-25 |
Prosion–10xDNA: investment, 202205 existent 7-figure seed investment by 10xDNA |
2023-05-23 |
Smartbax–Boehringer: investment, 202305 seed financing round totalling €1.2m incl existing investor BIVF |
2023-05-23 |
Smartbax–High-Tech Gründerfonds: investment, 202305 seed financing round totalling €1.2m incl new investor HTGF |
2023-05-23 |
Smartbax–SEVERAL: investment, 202305 seed financing round €1.2m from BIVF + HTGF |
2023-05-23 |
Smartbax–Trophic Communications: public relations, 202305 service existent by Trophic |
2023-05-23 |
Oncimmune–Freenome: investment, 202305 acquisition of Oncimmune Ltd by Freenome |
2023-05-22 |
VectivBio–Ironwood: investment, 202305–202306 acquisition $1b net of cash/debt cash tender offer at $17/share |
2023-05-21 |
Traceless Materials–Germany (govt): grant, 202305– BMUV funding €5.1m for construction of demonstration plant |
2023-05-19 |
Boundless Bio–Bayer: investment, 202305 financing round Series C totalling $100m incl new + co-lead investor Leaps by Bayer |
2023-05-16 |
Boundless Bio–Nextech: investment, 202305 financing round Series C totalling $100m incl existing + co-investor Nextech Invest |
2023-05-16 |
Boundless Bio–SEVERAL: investment, 202305 financing round Series C $100m co-led by Leaps by Bayer + RA Capital |
2023-05-16 |
Boundless Bio–Sophia Genetics: molecular diagnostics, 202305 existent collab develpm ecDNA Harboring Oncogenes clinical trial assay ECHO for BBI-355 |
2023-05-16 |
Dualyx–High-Tech Gründerfonds: investment, 202305 financing round Series A totalling €40m incl existing + co-investor HTGF |
2023-05-15 |
Dualyx–SEVERAL: investment, 202305 financing round Series A €40m co-led by Fountain Heathcare Partners + Forbion + Andera Partners |
2023-05-15 |
Exazyme–AIX Ventures: investment, 202305 seed financing round totalling €2m from AIX Ventures + Atlantic Labs |
2023-05-15 |
Exazyme–Altantic Labs: investment, 202305 seed financing round totalling €2m from AIX Ventures + Atlantic Labs |
2023-05-15 |
Exazyme–SEVERAL: investment, 202305 seed financing round €2m from AIX Ventures + Atlantic Labs |
2023-05-15 |
Nia Health–Adesso: investment, 202305 seed financing round totalling €3.5m incl co-investor Adesso Ventures |
2023-05-15 |
Nia Health–High-Tech Gründerfonds: investment, 202305 seed financing round totalling €3.5m incl lead investor HTGF |
2023-05-15 |
Nia Health–PERSON: investment, 202305 seed financing round totalling €3.5m incl co-investor fund of Kurt Schwarz |
2023-05-15 |
Nia Health–Piabo PR: public relations, 202305 service existent by Piabo PR |
2023-05-15 |
Nia Health–SEVERAL: investment, 202305 seed financing round €3.5m led by HTGF |
2023-05-15 |
Nia Health–Ventura BioMed Investors: investment, 202305 seed financing round totalling €3.5m incl co-investor Venture BioMed Investors |
2023-05-15 |
Repare Therapeutics–Vivlion: gene editing, 202305– supply of PRICSR CRISPR gRNA libraries for synthetic lethal screening by Vivlion |
2023-05-11 |
UCB–Ariceum Therapeutics: targeted radiopharmaceuticals, 202305– collab strategic r+d for TRTs for solid tumours + immune-related diseasees |
2023-05-11 |
Bayer–Bicycle Therapeutics: Bicycle technology, 202305– strategic collab $45m upfront + $1.7b milestones for targeted radiopharmaceuticals |
2023-05-10 |
DiogenX–AdBio Partners: investment, 202305 financing round Series A totalling €27.5m incl existing + co-investor AdBio Partners |
2023-05-10 |
DiogenX–Boehringer: investment, 202305 financing round Series A totalling €27.5m incl existing + co-lead investor Boehringer Ingelheim Venture Fund |
2023-05-10 |
DiogenX–Juvenile Diabetes Research Foundation: investment, 202305 financing round Series A totalling €27.5m incl existing + co-investor JDRF T1D Fund |
2023-05-10 |
DiogenX–Lilly: investment, 202305 financing round Series A totalling €27.5m incl new + co-investor Eli Lilly |
2023-05-10 |
DiogenX–Omnes Capital: investment, 202305 financing round Series A totalling €27.5m incl new + co-investor Omnes |
2023-05-10 |
DiogenX–Roche: investment, 202305 financing round Series A totalling €27.5m incl new + co-lead investor Roche Venture Fund |
2023-05-10 |
DiogenX–SEVERAL: investment, 202305 financing round Series A €27.5m led by BIVF + Roche Venture Fund |
2023-05-10 |
Ascend GCTx–4BIO Ventures: investment, 202305c financing round Series A incl co-investor 4BIO Capital |
2023-05-09 |
Ascend GCTx–Ajinomoto: investment, 202305c financing round Series A incl co-investor Ajinomoto Co Inc |
2023-05-09 |
Ascend GCTx–Carlyle: investment, 202305c financing round Series A incl co-lead investor Abingworth |
2023-05-09 |
Ascend GCTx–Cathay Capital: investment, 202305c financing round Series A incl co-investor Cathay Health |
2023-05-09 |
Ascend GCTx–DCVC: investment, 202305c financing round Series A incl co-investor DCVC Bio |
2023-05-09 |
Ascend GCTx–Deerfield: investment, 202305c financing round Series A incl co-investor Deerfield Management |
2023-05-09 |
Ascend GCTx–Digitalis Ventures: investment, 202305c financing round Series A incl co-investor Digitalis Ventures |
2023-05-09 |
Ascend GCTx–Petrichor Healthcare: investment, 202305c financing round Series A incl co-lead investor Petrichor |
2023-05-09 |
Ascend GCTx–Ramarketing: public relations, 202305 service existent Ramarketing is media contact |
2023-05-09 |
Ascend GCTx–SEVERAL: investment, 202305c financing round Series A bringing total raised to $132.5m led by Abingworth + Petrichor |
2023-05-09 |
Cambridge Research Biochemicals–Biosynth: investment, 202305 acquisition of CRB by Biosynth |
2023-05-09 |
PolyPeptide–Numaferm: peptide synthesis, 202305– collab €na Preferred Partner Collaboration Agreement for peptide development + production |
2023-05-09 |
Roche–Zion Pharma: tyrosine kinase inhibitor, 202305– acqisition ww rights $70m ufpront + near-term MS + $610m milestones + royalties to ZN-A-1041 |
2023-05-09 |
Midwest Biosolutions–Bionter: analytical instruments, 202305– collab Midwest Bio to promote + sell Bionter products + services in the US |
2023-05-08 |
Zontal–Bruker: investment, 202305 acquisition €na of Zontal by Bruker |
2023-05-08 |
Bicycle Therapeutics–Helmholtz: Bicycle radio conjugates, 202305– collab to discovery + develop BRCs for a range of oncology targets with DKFZ |
2023-05-04 |
Anavo Therapeutics–ABP (NL): investment, 202305 seed financing round extenstion totalling €8.5m incl existing investor Inkef Capital |
2023-05-02 |
Anavo Therapeutics–Bioqube Ventures: investment, 202305 seed financing round extenstion totalling €8.5m incl existing investor Bioqube Ventures |
2023-05-02 |
Anavo Therapeutics–Merck (DE): investment, 202305 seed financing round extenstion totalling €8.5m incl existing investor M Ventures |
2023-05-02 |
Anavo Therapeutics–Merck (US): investment, 202305 seed financing round extenstion totalling €8.5m incl new investor MRL Ventures Fund |
2023-05-02 |
Anavo Therapeutics–Otsuka: investment, 202305 seed financing round extenstion totalling €8.5m incl existing investor Taiho Ventures |
2023-05-02 |
Anavo Therapeutics–SEVERAL: investment, 202305 seed financing round extenstion €8.5m with new investor MRL Ventures + all existing investors |
2023-05-02 |
Medigene–Helmholtz: cancer immunotherapy, 202305– license ww excl to CD40L-CD28 costimulatory swith receptor from Helmholtz Munich |
2023-05-02 |
Ten23 Health–Bionter: particle counting, 202305– collab developm of methods incl installation of EVE particle counter at Ten23 Heatlh |
2023-05-02 |
VectivBio–Forbion: investment, 202305 existent shareholder Forbion |
2023-05-01 |
Clickmer Systems–APIS Assay Technologies: investment, 202204 acquisition of Clickmer Systems for single-digit €m by APIS Assay Technologies Ltd |
2023-04-25 |
Forbion–SEVERAL: investment, 202304 final close of Forbion Growth Opportunities Fund II with addit €130m bringing total fund size to hard cap €600m |
2023-04-19 |
Forbion–SEVERAL: investment, 202304 final close €750m of Forbion Ventures Fund VI |
2023-04-19 |
Gilde Investment–SEVERAL: investment, 202304 announced new Gilde Healthcare Venture&Growth VI with €600m investor commitments |
2023-04-19 |
Ariceum Therapeutics–Andera Partners: investment, 202304 financing round Series A extension totalling €22.75m incl new + co-lead investor Andera |
2023-04-18 |
Ariceum Therapeutics–Bellevue: investment, 202304 financing round Series A extension totalling €22.75m incl existing + co-investor Pureos Bioventures |
2023-04-18 |
Ariceum Therapeutics–Earlybird: investment, 202304 financing round Series A extension totalling €22.75m incl new + co-lead investor Earlybird VC |
2023-04-18 |
Ariceum Therapeutics–SEVERAL: investment, 202304 financing round Series A extension €22.75m bringing total Series A to €47.75m |
2023-04-18 |
Zetta Genomics–Apex Ventures: investment, 202304 2nd seed financing round totalling £1.9m incl existing + co-investor Apex Ventures |
2023-04-18 |
Zetta Genomics–SEVERAL: investment, 202304 2nd seed financing round £1.9m with led by Nina Capital |
2023-04-18 |
Zetta Genomics–Univ Cambridge: investment, 202304 2nd seed financing round totalling £1.9m incl existing + co-investor Cambridge Enterprise |
2023-04-18 |
Bio-Techne–Lunaphore: spatial omics, 202304– collab strategic partnership integrating COMET system with RNAscope technology |
2023-04-17 |
Complement Therapeutics–BioGeneration Ventures: investment, 202304 financing round Series A totalling €72m incl exising + co-investor BGV |
2023-04-17 |
Complement Therapeutics–Cambridge Innovation Capital: investment, 202304 financing round Series A totalling €72m incl new + co-investor CIC |
2023-04-17 |
Complement Therapeutics–Forbion: investment, 202304 financing round Series A totalling €72m incl exising + co-lead investor Forbion |
2023-04-17 |
Complement Therapeutics–Gimv: investment, 202304 financing round Series A totalling €72m incl new + lead investor Gimv |
2023-04-17 |
Complement Therapeutics–Hadean Ventures: investment, 202304 financing round Series A totalling €72m incl new + co-investor Hadean Ventures |
2023-04-17 |
Complement Therapeutics–Panakès Partners: investment, 202304 financing round Series A totalling €72m incl new + co-investor Panakès Partners |
2023-04-17 |
Complement Therapeutics–Seroba: investment, 202304 financing round Series A totalling €72m incl new + co-investor Seroba Life Sciences |
2023-04-17 |
Complement Therapeutics–SEVERAL: investment, 202304 financing round Series A €72m led by new investor Gimv |
2023-04-17 |
Syngenta–Ginkgo Bioworks: seed technology, 202304– collab research using protein engineering + uHTS technologies to design + develop new plant traits |
2023-04-17 |
CellPhenomics–Kyan Therapeutics: drug development technology, 202304– collab combi Optim.AI technology with PD3D technology for drug development |
2023-04-14 |
Alentis Therapeutics–Bellevue: investment, 202304 financing round Series C totalling $105m incl existing + co-investor BB Pureos Bioventures |
2023-04-13 |